Indo Borax & Chemicals has availed ₹225 crore in funding from a lending institution to finance the acquisition of equity shares of Kronox Lab Sciences Limited. The transaction was completed on September 23, 2026.

This capital infusion supports the company's strategic expansion into the laboratory sciences sector through the targeted acquisition. The move aligns with previous disclosures made by the company regarding its intent to acquire shares in Kronox Lab Sciences.

Regulatory Compliance and Disclosures

The company filed an intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates timely disclosure of material events that may affect the stock price or investor interests.

Indo Borax stated it will make further disclosures as required by applicable SEBI Listing Regulations. The filing was signed by Pravin Chavan, Company Secretary & Compliance Officer, on September 24, 2026.

Transaction Details

What the Numbers Show

The ₹225 crore funding represents a significant capital outlay dedicated entirely to external growth via acquisition rather than internal operational expenditure. By securing debt financing specifically for this equity purchase, Indo Borax preserves its existing cash reserves while expanding its portfolio into the lab sciences domain. The specific allocation of funds highlights a focused strategic pivot or diversification effort, contingent on the successful closure of the share acquisition.

Indo Borax & Chemicals will participate in a virtual group meeting organized by Arihant Capital on September 28, 2026. The session is scheduled from 12:00 pm to 1:00 pm IST as part of the Bharat Connect Conference.

The company confirmed in a filing to stock exchanges that discussions will be based strictly on publicly available information. Management stated that no unpublished price sensitive information (UPSI) is intended to be discussed during the interaction.

Meeting details

The interaction falls under the Rising Stars - September 2026 conference series. The mode of participation is virtual, allowing institutional investors and analysts to engage with company officials remotely.

Compliance and disclosure

The intimation was made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company Secretary and Compliance Officer, Pravin Chavan, signed the document digitally on September 23, 2026.

The filing noted that changes to the schedule may occur due to exigencies on the part of the host or participants. Investors are advised to rely on official exchange disclosures for any updates regarding the meeting status.